Cabazitaxel suppresses colorectal cancer cell growth via enhancing the p53 antitumor pathway
There were approximately 1.93 million new cases and 940 000 deaths from colorectal cancer in 2020. The first‐line chemotherapeutic drugs for colorectal cancer are mainly based on 5‐fluorouracil, although the use of these drugs is limited by the development of drug resistance. Consequently, there is...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-11-01
|
| Series: | FEBS Open Bio |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/2211-5463.13290 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849322400109297664 |
|---|---|
| author | Wen Zhang Ruiqian Sun Yongjun Zhang Rong Hu Qian Li Weili Wu Xinyu Cao Jiajian Zhou Jianfeng Pei Ping Yuan |
| author_facet | Wen Zhang Ruiqian Sun Yongjun Zhang Rong Hu Qian Li Weili Wu Xinyu Cao Jiajian Zhou Jianfeng Pei Ping Yuan |
| author_sort | Wen Zhang |
| collection | DOAJ |
| description | There were approximately 1.93 million new cases and 940 000 deaths from colorectal cancer in 2020. The first‐line chemotherapeutic drugs for colorectal cancer are mainly based on 5‐fluorouracil, although the use of these drugs is limited by the development of drug resistance. Consequently, there is a need for novel chemotherapeutic drugs for the efficient treatment of colorectal cancer patients. In the present study, we screened 160 drugs approved by the Food and Drug Administration and identified that cabazitaxel (CBT), a microtube inhibitor, can suppress colony formation and cell migration of colorectal cancer cells in vitro. CBT also induces G2/M phase arrest and apoptosis of colorectal cancer cells. Most importantly, it inhibits the growth of colorectal cancer cell xenograft tumors in vivo. Transcriptome analysis by RNA‐sequencing revealed that Tub family genes are abnormally expressed in CBT‐treated colorectal cancer cells. The expression of several p53 downstream genes that are associated with cell cycle arrest, apoptosis, and inhibition of angiogenesis and metastasis is induced by CBT in colorectal cancer cells. Overall, our results suggests that CBT suppresses colorectal cancer by upregulating the p53 pathway, and thus CBT may have potential as an alternative chemotherapeutic drug for colorectal cancer. |
| format | Article |
| id | doaj-art-ddfa0a02de124e0fac023bd8880ae5e5 |
| institution | Kabale University |
| issn | 2211-5463 |
| language | English |
| publishDate | 2021-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | FEBS Open Bio |
| spelling | doaj-art-ddfa0a02de124e0fac023bd8880ae5e52025-08-20T03:49:22ZengWileyFEBS Open Bio2211-54632021-11-0111113032305010.1002/2211-5463.13290Cabazitaxel suppresses colorectal cancer cell growth via enhancing the p53 antitumor pathwayWen Zhang0Ruiqian Sun1Yongjun Zhang2Rong Hu3Qian Li4Weili Wu5Xinyu Cao6Jiajian Zhou7Jianfeng Pei8Ping Yuan9Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Disease The Sixth Affiliated Hospital of Sun Yat‐sen University Guangzhou ChinaGuangdong Country Garden School Foshan City ChinaDermatology Hospital Southern Medical University Guangzhou ChinaGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Disease The Sixth Affiliated Hospital of Sun Yat‐sen University Guangzhou ChinaGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Disease The Sixth Affiliated Hospital of Sun Yat‐sen University Guangzhou ChinaGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Disease The Sixth Affiliated Hospital of Sun Yat‐sen University Guangzhou ChinaInstitute of Clinical Medical Sciences,， Center of Respiratory Medicine China‐Japan Friendship Hospital Beijing ChinaDermatology Hospital Southern Medical University Guangzhou ChinaCenter for Quantitative Biology,， Academy for Advanced Interdisciplinary Studies Peking University Beijing ChinaGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Disease The Sixth Affiliated Hospital of Sun Yat‐sen University Guangzhou ChinaThere were approximately 1.93 million new cases and 940 000 deaths from colorectal cancer in 2020. The first‐line chemotherapeutic drugs for colorectal cancer are mainly based on 5‐fluorouracil, although the use of these drugs is limited by the development of drug resistance. Consequently, there is a need for novel chemotherapeutic drugs for the efficient treatment of colorectal cancer patients. In the present study, we screened 160 drugs approved by the Food and Drug Administration and identified that cabazitaxel (CBT), a microtube inhibitor, can suppress colony formation and cell migration of colorectal cancer cells in vitro. CBT also induces G2/M phase arrest and apoptosis of colorectal cancer cells. Most importantly, it inhibits the growth of colorectal cancer cell xenograft tumors in vivo. Transcriptome analysis by RNA‐sequencing revealed that Tub family genes are abnormally expressed in CBT‐treated colorectal cancer cells. The expression of several p53 downstream genes that are associated with cell cycle arrest, apoptosis, and inhibition of angiogenesis and metastasis is induced by CBT in colorectal cancer cells. Overall, our results suggests that CBT suppresses colorectal cancer by upregulating the p53 pathway, and thus CBT may have potential as an alternative chemotherapeutic drug for colorectal cancer.https://doi.org/10.1002/2211-5463.13290cabazitaxelcolorectal cancer cellHCT116RNA‐sequencingxenograft |
| spellingShingle | Wen Zhang Ruiqian Sun Yongjun Zhang Rong Hu Qian Li Weili Wu Xinyu Cao Jiajian Zhou Jianfeng Pei Ping Yuan Cabazitaxel suppresses colorectal cancer cell growth via enhancing the p53 antitumor pathway FEBS Open Bio cabazitaxel colorectal cancer cell HCT116 RNA‐sequencing xenograft |
| title | Cabazitaxel suppresses colorectal cancer cell growth via enhancing the p53 antitumor pathway |
| title_full | Cabazitaxel suppresses colorectal cancer cell growth via enhancing the p53 antitumor pathway |
| title_fullStr | Cabazitaxel suppresses colorectal cancer cell growth via enhancing the p53 antitumor pathway |
| title_full_unstemmed | Cabazitaxel suppresses colorectal cancer cell growth via enhancing the p53 antitumor pathway |
| title_short | Cabazitaxel suppresses colorectal cancer cell growth via enhancing the p53 antitumor pathway |
| title_sort | cabazitaxel suppresses colorectal cancer cell growth via enhancing the p53 antitumor pathway |
| topic | cabazitaxel colorectal cancer cell HCT116 RNA‐sequencing xenograft |
| url | https://doi.org/10.1002/2211-5463.13290 |
| work_keys_str_mv | AT wenzhang cabazitaxelsuppressescolorectalcancercellgrowthviaenhancingthep53antitumorpathway AT ruiqiansun cabazitaxelsuppressescolorectalcancercellgrowthviaenhancingthep53antitumorpathway AT yongjunzhang cabazitaxelsuppressescolorectalcancercellgrowthviaenhancingthep53antitumorpathway AT ronghu cabazitaxelsuppressescolorectalcancercellgrowthviaenhancingthep53antitumorpathway AT qianli cabazitaxelsuppressescolorectalcancercellgrowthviaenhancingthep53antitumorpathway AT weiliwu cabazitaxelsuppressescolorectalcancercellgrowthviaenhancingthep53antitumorpathway AT xinyucao cabazitaxelsuppressescolorectalcancercellgrowthviaenhancingthep53antitumorpathway AT jiajianzhou cabazitaxelsuppressescolorectalcancercellgrowthviaenhancingthep53antitumorpathway AT jianfengpei cabazitaxelsuppressescolorectalcancercellgrowthviaenhancingthep53antitumorpathway AT pingyuan cabazitaxelsuppressescolorectalcancercellgrowthviaenhancingthep53antitumorpathway |